Patents by Inventor Grant D. Carlson

Grant D. Carlson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for diagnosing benign prostatic diseases and prostatic adenocarcinoma using an algorithm
    Patent number: 6140065
    Abstract: The present invention relates to novel reflex methods for identifying a male human patient as suitable for diagnosis either benign prostatic diseases (BPD), (such as benign prostatic hyperplasia, prostatitis, or glandular atrophy), or prostatic adenocarcinoma (CAP) without requiring a biopsy. The method requires measuring two biochemical markers and knowing the patient age. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 4.0 ng/mL and 20.0 ng/mL, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. The patient's age is noted, rounding down to an integral numbers of years. The two measured values and the age are entered into a particular identifying algorithm which is derived from a logistic regression model. If a value of greater than about 0.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: October 31, 2000
    Assignee: Dianon Systems, Inc.
    Inventors: Grant D. Carlson, Christina Beth Cavallo-Calvanese
  • Methods for diagnosing benign prostatic diseases
    Patent number: 6100049
    Abstract: The present invention relates to novel methods for diagnosing benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy, in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between about 2.5 ng/ml and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD. Optionally, if the patient has a total PSA level of between 10.1 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient can also be measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: August 8, 2000
    Inventors: Albert A. Luderer, Grant D. Carlson, Robert P. Thiel, Thomas F. Soriano, William J. Kramp
  • Methods for diagnosing benign prostatic diseases
    Patent number: 5912135
    Abstract: The present invention relates to novel methods for diagnosing benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy, in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between about 2.5 ng/ml and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD. Optionally, if the patient has a total PSA level of between 10.1 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient can also be measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: June 15, 1999
    Inventors: Albert A. Luderer, Grant D. Carlson, Robert P. Thiel, Thomas F. Soriano, William J. Kramp
  • Methods for diagnosing prostatic adenocarcinoma
    Patent number: 5710007
    Abstract: The present invention relates to a method for diagnosing prostatic adenocarcinoma (CAP) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is less than about 7%, then the patient is diagnosed as having CAP. The present method can also be used on patients that have a total PSA of at least 10.1 ng/ml, but have also had a negative prostate biopsy.
    Type: Grant
    Filed: September 29, 1995
    Date of Patent: January 20, 1998
    Inventors: Albert A. Luderer, Grant D. Carlson, Ya-Ting Chen, Thomas F. Soriano, Robert P. Thiel
  • Methods for diagnosing benign prostatic hyperplasia
    Patent number: 5698402
    Abstract: The present invention relates to a method for diagnosing benign prostatic hyperplasia (BPH) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml, (4.0 ng/ml for those 60 years or over), and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPH.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: December 16, 1997
    Assignee: Dianon Systems, Inc.
    Inventors: Albert A. Luderer, Grant D. Carlson, Robert P. Thiel, Thomas F. Soriano, William J. Kramp